Loading...
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer
IMPORTANCE: The BEACON trial showed that combination therapy with encorafenib (BRAF inhibitor) and cetuximab (EGFR inhibitor) was associated with prolonged overall survival compared with standard chemotherapy in patients with metastatic BRAF variant colorectal cancer. However, the cost-effectiveness...
Na minha lista:
| Udgivet i: | JAMA Netw Open |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Medical Association
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7804917/ https://ncbi.nlm.nih.gov/pubmed/33433598 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.33441 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|